2023年1月5日

100 B係列擴展融資共同通過新生控股/ S, Catalio資本管理和共生,與新的和現有投資者的參與,包括跳躍由拜耳和現代化,以及初始係列B導致烤瓷健康科學,Farallon Capital管理、現金和全球領先的投資公司擴展跑道凝固Metagenomi下一代基因編輯領域中的領導地位,使Metagenomi進步的主要治療方案臨床研究,基因藥物和擴張的管道,由最大的專有下一代基因編輯平台Ray Camahort博士新生企業的合夥人Novo控股的全資子公司,以觀察員身份加入Metagenomi董事會05年1月,2023年是東部標準時間07:00維爾,加州——(業務線)——Metagenomi,基因藥物公司全資的多功能組合,下一代基因編輯係統,今天宣布的一係列B擴展融資,共同通過新生控股/ S, Catalio資本管理和共生,新的和現有投資者的參與。本係列100美元融資帶來的總收益275美元,超過30投資集團參與。與融資,Ray Camahort博士新生企業的合夥人將加入Metagenomi董事會作為觀察員。“在Novo控股,我們的目的是改善人們的健康和社會的可持續發展和地球。Metagenomi繼續顯示一個令人印象深刻的記錄快速發展的新型基因編輯係統和推進他們通過臨床驗證,”雷說Camahort博士新生企業的合夥人。Metagenomi”相結合的新一代技術平台,臨床進展,大量驗證和強勁的投資者合作,我們相信該公司將迅速開發療法治療範圍廣泛的遺傳疾病。”,一個健康的現金跑道的高跟鞋與現代化和Ionis製藥成功的夥伴關係,這些額外的資金將使Metagenomi推進通過臨床前開發和臨床治療計劃的鉛概念證明。此外,該公司計劃提名其專有的基因藥物管道額外的治療目標,得益於其自動發現引擎和多功能基因編輯工具箱,擴展到額外的臨床前概念驗證研究。“關閉本係列的B擴展融資證明了我們的重大進展在過去的一年。我們進一步擴大全資的工具箱,下一代基因編輯技術,開始了我們的第一個非人類靈長類動物(額定馬力)體內基因編輯概念驗證研究和加強我們的戰略業務發展聯盟,”布萊恩·c·托馬斯說,Metagenomi的創始人和CEO。“這額外的資本為我們提供了最初的臨床裏程碑的可見性以及擴大體內基因編輯應用程序的管道。” About Metagenomi Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co About Novo Holdings Novo Holdings is a holding and investment company that is responsible for managing the assets of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes (the Novo Group companies) and manages an investment portfolio, with a long-term return perspective. Novo Holdings invests in life science companies of all stages of development and also manages a broad portfolio of equities, bonds, real estate and infrastructure assets as well as private equity investments. As of year-end 2021, Novo Holdings had total assets of USD 106 billion.